Loberg Philip Walden Jr 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Dec 27, 2010
Insider Transaction Report
Form 4
Loberg Philip Walden Jr
EVP, Interim CFO
Transactions
- Award
Restricted Share Units
2010-12-22+671→ 20,671 total→ Common Stock, no par value (671 underlying)
Footnotes (3)
- [F1]Each Restricted Share Unit (RSU) represents a contingent right to receive between zero and three shares of Common Stock, no par value, of Valeant Pharmaceuticals International, Inc. (the "Common Stock"), subject to performance based vesting criteria. See note (3).
- [F2]Represents dividend equivalents accrued on RSUs as a result of a dividend paid on the Common Stock on December 22, 2010.
- [F3]The performance based RSUs will vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of Common Stock, respectively, with early vesting possible at higher TSR levels.